Who is sponsoring NCT03939871?

NCT03939871 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT03939871?

Interventions in NCT03939871: fluvestrant + oral vinorelbine.

What condition does NCT03939871 study?

NCT03939871 studies Hormone Receptor Positive Advanced Breast Cancer.

Is NCT03939871 still recruiting?

NCT03939871 is currently status unknown. Last updated 23 June 2020.

Last reviewed 2020-06-23 · How we verify

NCT03939871

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Status unknown Phase 2 Last updated 23 June 2020

What this trial tests

Phase 2 trial testing fluvestrant + oral vinorelbine in Hormone Receptor Positive Advanced Breast Cancer in 30 participants. Status unknown.

Timeline

12 December 2017

Primary endpoint
12 December 2020

12 December 2020

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	12 December 2017
Primary completion	12 December 2020
Estimated completion	12 December 2020
Sites	1 location across China

Drugs / interventions tested

fluvestrant + oral vinorelbine — full drug profile →

Conditions studied

Hormone Receptor Positive Advanced Breast Cancer — all drugs for Hormone Receptor Positive Advanced Breast Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 70, female only, with Hormone Receptor Positive Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center phase II study designed to evaluated the efficacy and safety of fulvestrant in combination with oral vinorelbine in hormone receptor-positive advanced breast cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03939871 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 23 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939871.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing